Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows

Quick Summary:

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Lindsey Leake

Category: EconomyBusiness

Markets: United States

Topics: NIH AstraZeneca Merck NYU Langone Health Women Fortune 500 Companies Cancer Editor's Picks Cancer research Genetics Biomedical research Drugs Doctors Cancer treatments Clinical trials Deaths Breast cancer Death Medicine Health Oncology National Institutes of Health Pharmaceutical Industry CANCER TREATMENT Medical Research

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-12-20 @ 21:30:00 (12 hours ago)

News Timezone: GMT +8:00

News Source URL: fortune.com

Language: English

Article Length: 22 words

Reading Time: 1 minutes read

Sentences: 4 lines

Sentence Length: 6 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Fortune

News ID: 24571086

View Article Analysis

About Fortune

Main Topics: EconomyBusiness

Official Website: fortune.com

Update Frequency: 60 posts per day

Year Established: 1929

Headquarters: United States

News Last Updated: 9 hours ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #95

Publisher Details

Frequently Asked Questions